Protagenic Therapeutics, Inc.\new Free Cash Flow (FCF) History (PTIX)

Protagenic Therapeutics, Inc.\new reported −$2.8M in free cash flow for fiscal 2026, an increase of $1.0M from the previous fiscal year.

View full Protagenic Therapeutics, Inc.\new company overview

Protagenic Therapeutics, Inc.\new free cash flow by year

Protagenic Therapeutics, Inc.\new annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20262026-03-31−$2.8M$1.0M
20232023-12-31−$3.9M−$1.9M
20222022-12-31−$2.0M−$1.6M
20152015-06-30−$379,000$412,000
20142014-06-30−$791,000

Protagenic Therapeutics, Inc.\new free cash flow growth trends

Protagenic Therapeutics, Inc.\new's latest reported quarter, Q4 2015, generated −$58,485 in free cash flow, an increase of $28,515 year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Protagenic Therapeutics, Inc.\new filings at SEC.gov ↗